The randomized phase III BOSTON study evaluates “once-weekly XPOVIO® (selinexor) in combination with once-weekly Velcade® (bortezomib) and low-dose dexamethasone (SVd) compared to standard twice-weekly Velcade plus low-dose dexamethasone (Vd) in patients with multiple myeloma who have received one to three prior lines of therapy.” Karyopharm Therapeutics Inc. announced that “the BOSTON study met its primary endpoint of a statistically significant increase in progression-free survival (PFS).” Learn more about the phase III BOSTON clinical trial here.



Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.